What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

Varinder Rai, Regional Medicines Information Manager, London Medicines Information ServiceSource UKMiPublished 4 September 2018

Administration
Cardiovascular system disorders
Dalteparin
Enoxaparin
Haematological disorders
Tinzaparin
Travel Medicine

This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

Attachments